IntelGenx Technologies Corp is a Canada-based drug delivery company focused on the development of oral immediate-release and controlled-release products and on developing pharmaceutical products based on its drug delivery technologies. Its product development efforts are based upon over three delivery platform technologies, such as VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology, and AdVersa, a mucoadhesive tablet technology. The VersaFilm technology consists of a thin (25 to 35 micron) polymeric film consisting of the United States Pharmacopeia (USP) components for use in food, pharmaceutical and cosmetic products. Its Multilayer Tablet platform technology allows for the development of oral controlled-release products. Its product portfolio includes INT0001/2004, INT0004/2006, INT0007/2006, INT0008/2007, INT0010/2006, INT0027/2011, INT0030/2011, INT0036/2013, INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015 and INT0043/2015.
No company officers listed.
During the most recent quarter, 90K shares were bought, and 500 shares were sold in insider trading.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.